Hiroki Shioya

Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis

Takaki Komiya, Kazutoyo Sato, Hiroki Shioya et al. · Clinical & Experimental Immunology · 2012 · 49 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS‐622) in humans

Hiromichi Suzuki, Toshitaka Kawaratani, Hiroki Shioya et al. · Biopharmaceutics & Drug Disposition · 1993 · 26 citations

Pharmacy, Pharmacokinetics, Pharmacology +8

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P₁ and S1P₅ Selective Agonist for the Treatment of Autoimmune Diseases

H. Kurata, Kensuke Kusumi, Kazuhiro Otsuki et al. · Journal of Medicinal Chemistry · 2017 · 23 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Development and Characterization of Conditionally Immortalized Gastric Epithelial Cell Lines from Transgenic Rats Harboring Temperature-Sensitive Simian Virus 40 Large T-antigen Gene.

Yoshiaki Tabuchi, Yūkō Arai, Shoichiro Ohta et al. · Cell Structure and Function · 2002 · 18 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +5

Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function

S. Furuta, Kendo Kiyosawa, Makoto Higuchi et al. · European Journal of Clinical Pharmacology · 1993 · 17 citations

Pharmacy, Pharmacokinetics, Pharmacology +16